Immunexpress Inc. published a study demonstrating the strong performance and clinical utility of using SeptiCyte RAPID in polytrauma patients to diagnose sepsis.
Public source
Publisher name
Public post
News Release! - just published a study which demonstrates the strong performance and clinical utility of using #SeptiCyte RAPID in polytrauma patients to diagnose sepsis.
Company
Immunexpress Inc.
We are pioneering the technology that analyzes the immune system to rapidly detect sepsis.
- Industry
- Biotechnology Research
- Location
- Seattle, US
- Company size
- 11–50 employees
About Immunexpress Inc.
Immunexpress is a privately owned company creating revolutionary molecular diagnostics for sepsis. The company has offices in Seattle, USA and Brisbane, Australia. Immunexpress's product pipeline aims to address the overwhelming unmet clinical needs of sepsis patients, as well as clinicians, payers and healthcare systems. Unlike the traditional approach to sepsis diagnosis, SeptiCyte® quantifies the specific molecular biomarkers from a patient's immune system ('host response'). Biomarkers capture signals from a patient's immune system in response to infection. These biomarkers may hold the key to early detection of sepsis, as well as guiding the use and timing of drugs and other therapies.
See moreLatest activity
Latest activity from Immunexpress Inc.
10 signals
Research & Knowledge
Immunexpress Inc. published a study revealing that sepsis can be identified with clinically useful accuracy within the first one to three hours of presentation.
Research & Knowledge
Immunexpress Inc. published a study revealing that sepsis can be identified with clinically useful accuracy within the first one to three hours of presentation.
Research & Knowledge
Immunexpress Inc. published a study demonstrating the strong performance and clinical utility of using SeptiCyte RAPID in polytrauma patients to diagnose sepsis.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Cytovale
Cytovale published a full breakdown of 30,000 unnecessary hospital days hiding in a sepsis workflow found by a health system.
Research & Knowledge
Loop Dx
Loop Dx published a Mini Review in Frontiers in Medical Technology co-authored with Erika P. Plata-Menchaca exploring which sepsis diagnostic technologies make it from biomarker discovery to regulated clinical use.
Research & Knowledge
Immundiagnostik, Inc.
Immundiagnostik, Inc. published an article exploring calprotectin MRP8/14, its role in inflammatory diseases, sample types, and its value in longitudinal research.
Products & Services
Inflammatix, Inc.
Inflammatix, Inc. launched TriVerity, a product designed to bring forward critical patient information for clinicians to make the first decision in sepsis cases.
Research & Knowledge
MeMed